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Commissioning in english nhs
Time to debate  
neoliberalism
Paton highlights the inadequacies of 
commissioning in the English NHS.1 One of the 
recent reports from the King’s Fund and Nuffield 
Trust he cites illustrates the complexities of the 
system, including the many models available 
(box).2
The system is designed to increase market 
forces in the NHS. However, the expense and the 
information asymmetry between primary and 
secondary care are more examples of how markets 
fail in healthcare policy.
For the past 30 years world governments have 
expected markets to solve all their problems, 
including in the public services. Market forces and 
private sector management practices (New Public 
Management) penetrate the whole public sector:
All public services have to be based on a 
diversity of independent providers who 
compete for business in a market governed 
by consumer choice. All across Whitehall, any 
policy option now has to be dressed up as 
“choice,” “diversity,” and “contestability”. 
These are the hallmarks of the “new model 
public service.”3
But the evidence base for market based policies 
in many public services is weak, so why has this 
approach become embedded across the public 
sector? One explanation from two Labour MPs in 
the last government:
After years in opposition and with the political 
and economic dominance of neoliberalism, 
New Labour essentially raised the white flag 
and inverted the principle of social democracy. 
Society was no longer to be master of the 
market, but its servant. Labour was to offer 
a more humane version of Thatcherism, in 
that the state would be actively used to help 
people survive as individuals in the global 
economy—but economic interests would 
always call all the shots.4
It is now time for the medical profession to 
question the underlying political and economic 
philosophy of neoliberalism that has dominated 
the political landscape for the past 30 years. 
The charge has been led by the Australian prime 
minister, Kevin Rudd, in an 8000 word polemic.5 
We should at least start some debate.
Clive Peedell consultant clinical oncologist, Middlesbrough  
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The market delusion
Paton is right that the idea of general practice 
commissioning is recurring.1 Politicians realise 
that people trust their general practitioners 
more than politicians or faceless commissioners 
in the health authority, primary care trust, or 
whatever the organisation is called at the time; 
a few enthusiastic GPs with an eye to improving 
services for their patients—and, possibly, their 
income—actively campaigning to do it better 
than the existing commissioning body; changes 
are made so that all GPs have to commission; 
and the enterprise fails because, once everybody 
has to do it, the incentives to a few pilot practices 
disappear, and, anyway, most GPs are more 
interested in being GPs than commissioners.
The idea of using a market to provide people 
with what they want is an illusion. Basic 
economic theory dictates that markets work 
in favour of consumers only when there is an 
oversupply. The health service is designed to 
be as “efficient” as possible, with oversupply 
seen as inefficiency to be ruthlessly eliminated 
(even when it is needed to cope with outbreaks 
or the stochastic nature of demand). In these 
circumstances, playing up the importance of 
providing choice is dishonest rhetoric.
Peter M B english consultant in public health, Surrey KT19 9XF 
petermbenglish@gmail.com
Competing interests: None declared.
Paton C. Commissioning in the English NHS. 1 BMJ 
2010;340:c1979. (15 April.)
Cite this as: BMJ 2010;340:c2522
oropharyngeal CanCer
Fastest increasing cancer in 
Scotland, especially in men
Mehanna and colleagues highlight the increasing 
incidence of oral and oropharyngeal cancer in 
the United Kingdom and its likely association 
with sexually transmitted human papilloma virus 
(HPV).1 However, by reporting oropharyngeal 
cancer along with oral cancer the true rate of 
increase in oropharyngeal cancer is probably 
being masked.
Using data from the Scottish Cancer Registry, 
we found that oropharyngeal cancer now has the 
greatest rate of increase of any cancer in Scotland. 
We grouped cancers of the base of the tongue 
(C01), palate (C05), tonsil (C09), and oropharynx 
(C010). These codes were selected because they 
relate to the anatomically defined subsites of the 
oropharynx, enabling analysis of all registered 
cases. Incidence increased for each site, most for 
the tonsil and base of the tongue.
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Current commissioning models2
National commissioning groups•	
Supra-regional specialised groups•	
Regional specialised groups•	
Joint commissioning with local authority•	
Primary care trust (PCT)•	
Whole PCT practice based commissioning •	
(PBC)
Locality PBC consortium•	
Personal medical services (PMS) provider •	
organisation
Single practice•	
Personal health budgets•	
European age standardised (EAS) rates of various 
cancers by sex in Scotland, 1987-2006
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The figure shows that oropharyngeal cancer 
has overtaken both melanoma of the skin and 
adenocarcinoma of the oesophagus. In contrast, 
the incidence of invasive cancer of the cervix is 
decreasing. Linear regression yields an estimated 
2.9-fold increase in oropharyngeal cancer in men, 
and a 2.4-fold increase in women.
Oropharyngeal cancer associated with 
HPV seems to have a better prognosis than 
oropharyngeal cancer that is not. Population 
based data from the south east of Scotland 
showed a 34% difference in five year survival 
for oropharyngeal cancer in favour of women in 
a cohort diagnosed during 1999-2001 but no 
difference between men and women in a cohort 
diagnosed during 2003-5. Although 70% of 
patients present with stage IV disease, the five 
year survival for men in south east Scotland has 
now increased to 68%. Whether this change 
in survival relates to HPV status is unknown. 
However, with more younger patients surviving, 
the morbidity from treatment for individuals 
and the healthcare burden to the NHS will be 
significant. Perhaps vaccinating boys against HPV 
should be re-evaluated.
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australian data show increase
Australian data support the changing 
epidemiology of oropharyngeal cancer observed 
in other Western countries.1 Our study of 302 
oropharyngeal cancers from Sydney hospitals 
showed that the incidence of oropharyngeal 
squamous cell cancer positive for human 
papilloma virus (HPV) (p16) increased from 19% 
in 1987-90 to 47% in 2001-5 and 60% in 2005-6.2
On the basis of cancer incidence in Australia, 
we estimated that on average 1.56 cases of 
oropharyngeal squamous cell cancer per 100 000 
males per year were induced by HPV types 
targeted by the HPV vaccines during 2001-5.2 In 
Australia the quadrivalent HPV vaccine has been 
used in the school based, government funded 
programme for girls aged 12 to 13 and a two year 
catch-up programme for women aged up to 26. It 
has been approved for boys but is not subsidised 
by the government. Our data inform the debate 
on the merits of extending this vaccination 
programme to boys.
Randomised trials are needed to establish 
whether less intensive treatment is justified in 
patients with oropharyngeal cancer positive for 
HPV.1 Recent data suggest that any modification 
of treatment strategies based on HPV status 
may also need to take account of the effect of 
smoking in negating the beneficial effect of HPV 
on outcome.
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ColoreCtal CanCer
Secondary care data  
may mislead
Two methodological concerns make it tricky to 
interpret the findings of Jellema and colleagues’ 
systematic review of diagnosing colorectal 
cancer in primary care.1
Firstly, studies from settings other than 
primary care were included. Any population 
that has been selected, such as the referred 
population, will have different characteristics 
from the original population, reflecting the 
selection process.2 The authors recognise this, 
but we doubt that their solution of including only 
secondary care studies with a yield of cancer 
below that of the highest primary care study 
(15%) is correct. A study of antelopes cannot 
include giraffes, and it is no solution to select 
only small giraffes.
Secondly, the searches may have been too 
restrictive: perhaps the methodological filter 
eliminated some studies that meet the published 
selection criteria. We recently completed a similar 
review, restricting ourselves to truly primary care 
studies, and in our soon to be submitted paper 
we identified 23 studies, not the nine reported 
by Jellema and colleagues using similar criteria. 
Some of the additional studies are clearly 
germane—for example, two in the BMJ.3 4
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authors’ reply
Our research question was posed from a general 
practitioner’s perspective and addressed tests 
that a GP might use to identify an increased 
risk of colorectal cancer in patients consulting 
with lower abdominal complaints.1 2 We 
therefore excluded studies comparing the risk 
of colorectal cancer in patients with and without 
abdominal symptoms, such as the BMJ papers 
mentioned by Hamilton and colleagues.1
Our two reviews answer slightly different 
questions, and the results are complementary 
rather than overlapping. Our smaller number 
of papers has little to do with the use of a 
methodological filter: we used an extensive 
process of reference checking afterwards 
to ensure that we did not lose important or 
influential diagnostic studies.
We included settings other than primary care 
because primary care is defined differently in 
different countries. For example, facilities such 
as open access outpatient clinics may be directly 
accessible to patients with lower abdominal 
complaints. We also included two week referral 
clinics because they aim to identify patients 
with a high risk of colorectal cancer using signs, 
symptoms, and tests routinely used in general 
practice, and the patient populations may 
resemble those in general practice. However, 
as not all studies clearly reported whether an 
outpatient clinic was directly accessible to 
patients, we selected only those reporting a 
prevalence of colorectal cancer of less than 
15%, the highest prevalence reported in the 
primary care studies, to minimise spectrum bias.
Because the performance of diagnostic tests 
may vary between referred and non-referred 
populations, we presented data separately for 
primary care and other settings. Table 4 shows 
that the results do not clearly differ by setting.2 
In brief, we know that antelopes and small 
giraffes differ and we studied them separately, 
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but they seemed not to differ systematically 
on the characteristics we studied. However, 
the number of primary care studies was small, 
prohibiting firm conclusions.
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Negative results may 
falsely reassure
Primary care practitioners need to be clear 
about the difference between carrying out 
faecal occult blood tests in patients presenting 
with symptoms and the use of the test in bowel 
cancer screening programmes.1 In addition to not 
being recommended in patients presenting with 
symptoms of lower gastrointestinal cancer,2 faecal 
occult blood testing in the investigation of iron 
deficiency anaemia is unsupported by national 
guidelines.3
I work in a practice of 4000 patients and 
reviewed the cases of all those who had faecal 
occult blood tests in 2009. In all, 71 patients 
underwent testing. Indications were anaemia 
(47), dyspepsia (13), change of bowel habit (6), 
and rectal bleeding (5). Nine of the 11 patients 
with positive results were referred, and one was 
found to have a rectal carcinoma; 49 of the 60 
patients with negative result were not referred, 
but two met criteria for urgent referral.2 Patients 
with negative results were less likely to be 
followed-up and have a diagnosis documented in 
the electronic patient record.
Negative results may falsely reassure patients 
and general practitioners. Until the diagnostic 
performance of faecal occult blood testing 
in primary care is clearly established, a safe 
approach would be to see all patients after testing, 
regardless of their result. The need for other 
investigations or referral to secondary care could 
then be reassessed.
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Chlamydia infeCtion
Treatment may not be simple
My experience in general practice in a university 
population suggests that not all those who 
participate in asymptomatic screening for 
Chlamydia trachomatis are truly without 
symptoms.1 Patients may have obtained 
chlamydia screening kits without having a history 
taken by a health professional. Some may then 
admit to having had symptoms when given a 
positive result.
Lower abdominal pain, dyspareunia, abnormal 
vaginal bleeding, or abnormal vaginal or cervical 
discharge is suggestive of pelvic inflammatory 
disease. These women need assessment and then 
treatment with antibiotics other than the simple 
single dose of azithromycin. The only fully oral 
regimen in the guidelines on pelvic inflammatory 
disease from the British Association for Sexual 
Health and HIV (BASHH) is oral ofloxacin 400 mg 
with oral metronidazole 400 mg twice daily for 14 
days.2
Testicular or epididymal pain is suggestive 
of epididymo-orchitis. These men also need 
assessment and then treatment with antibiotics 
other than a single dose of azithromycin. 
BASHH guidelines on epididymo-orchitis most 
probably due to chlamydia infection or other 
non-gonococcal, non-enteric organisms currently 
recommend oral doxycycline 100 mg twice daily for 
10-14 days,3 although this guideline is currently 
being updated.4 The 2009 manual (revised 
December 2008) for the BASSH sexual transmitted 
infection foundation course still recommends 
doxycycline 100 mg twice daily for 14 days, with 
ofloxacin 200 mg twice daily for 14 days as an 
alternative.
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Don’t forget contraception
The review of Chlamydia trachomatis infections 
does not mention the potential interaction 
between antibiotics and combined hormonal 
contraception.1 The national chlamydia screening 
programme in England is aimed at all sexually 
active young people aged 15-24, and 54% of 
women aged 20-24 take the contraceptive pill.2 
Thus a large proportion of the women diagnosed 
through the screening programme will be using 
combined hormonal contraception. The Faculty 
of Sexual and Reproductive Health Care states 
that women using such contraception should be 
advised to use additional precautions when taking 
short term antibiotics because they may reduce 
the efficacy of the contraception.3 Abortion rates 
are highest among those aged 20-24 (32 per 1000 
women) but peak at the age of 19 (36 per 1000)4: 
there is no room for complacency about the risks 
associated with contraceptive failure.
The national strategy for sexual health and HIV 
aims to reduce the prevalence of undiagnosed 
sexually transmitted infections and rates of 
unintended pregnancy.5 Both aims must be 
remembered. When treating chlamydia, ask 
women if they are using combined hormonal 
contraception and if so advise them to avoid 
sexual contact to prevent not only re-infection but 
also potential pregnancy.
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Bristol Sexual Health Services, Bristol BS2 0JD  
lucinda.farmer@uHBristol.nhs.uk
Competing interests: None declared.
Kalwij S, Macintosh M, Baraitser P. Screening and 1 
treatment of Chlamydia trachomatis infections. BMJ 
2010;340:c1915. (21 April.)
Contraception and sexual heath, 2008/09. Opinions 2 
Survey Report No 41. Available at www.statistics.gov.uk/
downloads/theme_health/contra2008-9.pdf.
Faculty of Family Planning and Reproductive Health Care 3 
Clinical Effectiveness Unit. FFPRHC guidance (April 2005). 
Drug interactions with hormonal contraception. J Fam Plan 
Reprod Health Care 2005;31:139-51. Available at: www.BIO
M
ED
 IM
AG
IN
G
 U
N
IT
/S
PL
1050   BMJ | 15 May 2010 | VoluMe 340
letters
ffprhc.org.uk/admin/uploads/DrugInteractionsFinal.pdf.
Department of Health. Statistical bulletin. Abortion 4 
statistics, England and Wales: 2008. Available at: www.
dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/
documents/digitalasset/dh_099714.pdf.
Department of Health. The national strategy for sexual 5 
health and HIV. Available at: www.medfash.org.uk/
publications/documents/nat_shs-2001.pdf.
Cite this as: BMJ 2010;340:c2496
Screening needs more answers
Oakeshott and colleagues focused on clinical 
pelvic inflammatory disease in their evaluation 
of chlamydia screening.1 In infertility clinics, 
however, most women with tubal factor infertility 
and a high chlamydia antibody titre do not 
remember such a “typical” presentation of clinical 
signs and symptoms. The true outcome factor for 
cost effectiveness analyses is infertility, and more 
evidence about the clinical pathway of chlamydia 
infection is needed.2
Patient indicators (major outcomes averted) and 
societal indicators (prevention of transmission) are 
measures of the impact of screening for infectious 
diseases such as chlamydia. Two national trials, 
in the Netherlands and Australia,3 4 assess the 
impact of multiple screening rounds on forward 
transmission of chlamydia. Both indicators are 
needed to enable policy makers to prioritise 
prevention programmes.
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mortality and the pill
Wrong conclusions drawn, again
Hannaford and colleagues again made headlines 
in the popular press with their claim of a 12% 
decrease in the rate of death from any cause 
with oral contraceptive use,1 echoing the similar 
reduction in overall incidence of cancer claimed 
for their 2007 paper.2 However, once again,3 
detailed analysis suggests no such benefit, and 
even an opposite trend, given current trends of oral 
contraceptive use.
The lack of any significant life saving 
benefit is easily discerned from the difference 
between results for the full dataset and the 
general practice observation subset. Common 
sense suggests relying on the results from the 
smaller, better, dataset whenever statistical 
trends differ materially. However, the authors 
state: “The pattern of relative risks was 
different when we used the smaller general 
practice observation subset. In this subset, the 
adjusted relative risk for any death between 
ever users and never users was very close to 
unity (0.98, 0.88 to 1.10).”
Troubling trends of increased morbidity and 
mortality are also apparent in young nulliparous 
women, who constitute only a small minority 
of users in this study cohort but predominate 
among current users. For example, there was 
an almost threefold increase in death from any 
cause among women under 30, and a threefold 
increase in death from breast cancer for women 
under 45 between five and nine years after 
stopping use of oral contraceptives. Moreover, 
despite the decreased risk of death from breast 
cancer 10 or more years after stopping use of 
oral contraceptives in this latest report,1 the 
2007 report showed a dramatically increased 
incidence of breast cancer (relative risk 2.45) 
persisting up to 20 years after stopping use.2 
Such trends, however, are easily diluted by 
data from the majority of women in this study 
who overwhelmingly used oral contraceptives 
only after bearing one or more children and for 
a few years, contrary to current patterns of oral 
contraceptive use.
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authors’ reply
Brind thinks that common sense suggests that 
we should use the smaller, better, dataset when 
statistical trends differ materially.1 We presented 
both datasets so that readers can decide which 
one(s) they wish to use. Neither dataset showed 
substantial evidence of an increased risk of all 
cause mortality among ever users.
A higher proportion of observation periods in 
ever users related to current and recent pill use in 
the general practice observation dataset compared 
to the main dataset. This explains the increased 
risk of all circulatory disease and of breast cancer in 
ever users who had stopped oral contraception 5-9 
years previously in the general practice observation 
dataset. Similarly, in the age stratified analyses of 
the main dataset, ever users under 30 had much 
more current and recent use than older ever users. 
That ever users under 30 had nearly three times 
the risk of death of similarly aged never users is 
therefore not surprising.
Most of the adverse mortality effects of oral 
contraception occur in current and recent users, 
effects which diminish with time since stopping.2 
Our latest findings are compatible with our 
previous publications, and broadly in line with 
the collective evidence from other studies. A 
substantial proportion of the observation periods 
in the ever user group in the main dataset relates 
to pill use many years in the past. Unlike Brind, we 
think that the information provided by this dataset 
is valuable. We continue to interpret the results as 
not suggesting a substantial increased overall risk 
of death among ever users, especially since many 
events occurred long after the pill was stopped. 
Thus any medical treatment and death certification 
is unlikely to have been influenced by the doctor’s 
knowledge of a woman’s pill use.
We have tried to be careful when interpreting 
our results. Thus, we have stated clearly that the 
reduced overall risk of death in ever users in the 
main dataset may be due to selection processes or 
residual confounding rather than a direct effect of 
oral contraception.
Philip C Hannaford Grampian Health Board chair of primary care 
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